ADMA Biologics (NASDAQ: ADMA) is one of 290 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare ADMA Biologics to similar businesses based on the strength of its profitability, dividends, risk, analyst recommendations, earnings, valuation and institutional ownership.
This is a breakdown of recent recommendations and price targets for ADMA Biologics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|ADMA Biologics Competitors||1143||3450||11959||241||2.67|
ADMA Biologics presently has a consensus price target of $6.50, suggesting a potential upside of 81.56%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.28%. Given ADMA Biologics’ stronger consensus rating and higher possible upside, research analysts plainly believe ADMA Biologics is more favorable than its rivals.
Institutional & Insider Ownership
32.8% of ADMA Biologics shares are held by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 60.4% of ADMA Biologics shares are held by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares ADMA Biologics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|ADMA Biologics Competitors||-5,362.58%||-164.36%||-35.74%|
Earnings and Valuation
This table compares ADMA Biologics and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|ADMA Biologics||$10.66 million||-$19.51 million||-1.79|
|ADMA Biologics Competitors||$290.27 million||$35.99 million||52.50|
ADMA Biologics’ rivals have higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
ADMA Biologics has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, ADMA Biologics’ rivals have a beta of 2.54, meaning that their average stock price is 154% more volatile than the S&P 500.
ADMA Biologics beats its rivals on 7 of the 13 factors compared.
About ADMA Biologics
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.